Mural OncologyMURA
MURA
About: Mural Oncology PLC is a clinical-stage oncology company whose entire business is focused on discovering and developing immunotherapies that may meaningfully improve the lives of patients with cancer. By leveraging its core competencies in immune cell modulation and protein engineering, It has developed a portfolio of novel, investigational cytokine therapies designed to address areas of unmet need for patients with a variety of cancers. Its product candidate, Nemvaleukin is an investigational, engineered interleukin-2 cytokine designed to capture and expand the therapeutic benefits of high-dose recombinant human IL-2 while mitigating its hallmark toxicities.
Employees: 116
0
Funds holding %
of 7,433 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
89% more capital invested
Capital invested by funds: $10.6M [Q1] → $20M (+$9.44M) [Q2]
0% more first-time investments, than exits
New positions opened: 17 | Existing positions closed: 17
1.81% less ownership
Funds ownership: 48.72% [Q1] → 46.92% (-1.81%) [Q2]
4% less funds holding
Funds holding: 67 [Q1] → 64 (-3) [Q2]
60% less repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 20
63% less call options, than puts
Call options by funds: $459K | Put options by funds: $1.25M
Research analyst outlook
We haven’t received any recent analyst ratings for MURA.
Financial journalist opinion
Based on 4 articles about MURA published over the past 30 days
Neutral
Business Wire
6 days ago
MURA Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Mural Oncology plc Is Fair to Shareholders
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Mural Oncology plc (NASDAQ: MURA) to XOMA Royalty Corporation for $2.035 per share and, up to an additional $0.205 per share under certain conditions, is fair to Mural shareholders. Halper Sadeh encourages Mural shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@ha.
Neutral
GlobeNewsWire
6 days ago
Mural Oncology Announces Entry into Agreement to be Acquired by XRA 5 Corp., a wholly owned subsidiary of XOMA Royalty for between $2.035 and $2.24 in Cash per Share
WALTHAM, Mass., DUBLIN, Ireland and EMERYVILLE, Calif., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company (“Mural”), and XOMA Royalty Corporation (Nasdaq: XOMA), a biotechnology royalty aggregator (“XOMA Royalty”), announced today they have entered into a definitive agreement pursuant to which XRA 5 Corp., a newly formed company wholly owned by XOMA Royalty (“Sub”), has agreed to acquire the entire issued and to be issued share capital of Mural for cash (the “Acquisition”) subject to the satisfaction of the closing conditions set out in Appendix I of this Announcement (the “Conditions”), including approval by Mural Shareholders. Following a strategic review process, the Mural board of directors (the “Mural Board”) determined the acquisition and cash offer by XOMA Royalty is in the best interests of all Mural Shareholders and has approved the Acquisition. The Acquisition has also been approved by the boards of directors of XOMA Royalty and Sub.
Neutral
The Motley Fool
3 weeks ago
Mural Oncology (MURA) Q2 Loss Widens 49%
Mural Oncology (MURA) Q2 Loss Widens 49%
Neutral
GlobeNewsWire
3 weeks ago
Mural Oncology Announces Second Quarter Financial Results and Provides Business Update
Mural continues to explore strategic alternatives Estimates cash and cash equivalents of approximately $43 to $48 million at December 31, 2025, if it has not consummated a transaction or other strategic alternative by year end WALTHAM, Mass. and DUBLIN, Aug. 04, 2025 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA), today announced its financial results for the second quarter of 2025 and provided a business update.
Neutral
GlobeNewsWire
3 months ago
Mural Oncology Announces Number of Relevant Securities in Issue
WALTHAM, Mass. and DUBLIN, May 19, 2025 (GLOBE NEWSWIRE) -- In accordance with Rule 2.12 of the Irish Takeover Panel Act 1997, the Irish Takeover Rules 2022 (the “Irish Takeover Rules”), Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company, (“Mural”) confirms that, as of the close of business on May 1, 2025, the issued share capital of Mural was 17,268,881 ordinary shares with par value US$0.01 each (the “Ordinary Shares”).
Neutral
GlobeNewsWire
3 months ago
FORM 8.1(a) & (b) - Mural Oncology plc
Ap9 FORM 8.1(a) & (b) (Opening Position Disclosure) IRISH TAKEOVER PANEL OPENING POSITION DISCLOSURE UNDER RULE 8.1(a) AND (b) OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2022 BY AN OFFEROR OR AN OFFEREE 1. KEY INFORMATION (a) Full name of discloser: Mural Oncology plc (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient.
Positive
Zacks Investment Research
4 months ago
MURA Soars as it Explores Strategic Options Post Cancer Study Failures
Mural Oncology stock skyrockets after it begins exploring strategic alternatives to maximize shareholder value after the failure of two cancer studies for nemvaleukin alfa.
Neutral
GlobeNewsWire
4 months ago
Mural Oncology Announces Plans to Explore Strategic Alternatives
Following review of data from the phase 2 ARTISTRY-6 trial and previously announced results from the phase 3 ARTISTRY-7 trial, Mural will discontinue all clinical development of nemvaleukin With $144.4 million in cash as of December 31, 2024, Mural plans to explore strategic alternatives and will undertake a reduction in force of approximately 90% of employees WALTHAM, Mass. and DUBLIN, April 15, 2025 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company, today announced that following review of data from its phase 2 ARTISTRY-6 trial in melanoma and previously announced results from the phase 3 ARTISTRY-7 trial in platinum-resistant ovarian cancer, the company is discontinuing all clinical development of nemvaleukin alfa and plans to immediately commence the exploration of strategic alternatives focused on maximizing shareholder value.
Negative
Benzinga
5 months ago
Mural Oncology's Ovarian Cancer Combo Drug Trial Disappoints, Stock Plunges
On Tuesday, Mural Oncology plc MURA released data from the ARTISTRY-7 phase 3 trial of nemvaleukin alfa in combination with Merck & Co Inc's MRK Keytruda (pembrolizumab) vs. investigator choice single agent chemotherapy for platinum-resistant ovarian cancer.
Neutral
GlobeNewsWire
5 months ago
Mural Oncology Provides Update on Phase 3 ARTISTRY-7 Trial of Nemvaleukin in Combination with KEYTRUDA® (pembrolizumab) in Patients with Platinum-Resistant Ovarian Cancer
Based on overall survival data observed in interim analysis in platinum-resistant ovarian cancer, Mural will not progress trial to final analysis
Charts implemented using Lightweight Charts™